The new center will bring together pathology, computer science, cancer genomics, and immunogenomics to study which cancer patients can benefit from immunotherapy.
Two recent CRISPR-Cas9 viability screens in cancer cell lines were concordant across multiple metrics despite significant differences in experimental protocols.
Negative results in recent trials have highlighted the challenges that newer genomic test makers must overcome in proving methods for personalized CUP treatment.
A Phase II trial is pursuing molecularly targeted treatments for CUP as a different Phase III trial failed to find benefit for expression-based primary site therapies.
At the NCI's Childhood Cancer Data Initiative Symposium, speakers emphasized measures such as data harmonization and the need for longitudinal data collection.
The method allows for the annotation of cells by their genotype and capture of single-cell transcriptomes, even when the cells aren't morphologically distinct.
